Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (29)

2023

  1. APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke

    Frontiers in Neurology, Vol. 14

  2. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788

2022

  1. First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers

    Molecular Therapy - Nucleic Acids, Vol. 28, pp. 124-135

2019

  1. A Neutrophil Timer Coordinates Immune Defense and Vascular Protection

    Immunity, Vol. 50, Núm. 2, pp. 390-402.e10

2015

  1. Preliminary research on 1-(4-bromo-2-nitroimidazol-1-yl)-3-[18F]fluoropropan-2-ol as a novel brain hypoxia PET tracer in a rodent model of stroke

    European Journal of Medicinal Chemistry, Vol. 101, pp. 604-615

2014

  1. Oct-2 transcription factor binding activity and expression up-regulation in rat cerebral ischaemia is associated with a diminution of neuronal damage in vitro

    NeuroMolecular Medicine, Vol. 16, Núm. 2, pp. 332-349

  2. Rosiglitazone-induced CD36 up-regulation resolves inflammation by PPARγ and 5-LO-dependent pathways

    Journal of Leukocyte Biology, Vol. 95, Núm. 4, pp. 587-598

  3. The high-mobility group I-Y transcription factor is involved in cerebral ischemia and modulates the expression of angiogenic proteins

    Neuroscience, Vol. 269, pp. 112-130

2013

  1. Amelioration of Ischemic brain damage by peritoneal dialysis

    Journal of Clinical Investigation, Vol. 123, Núm. 10, pp. 4359-4363

  2. N2 neutrophils, novel players in brain inflammation after stroke: Modulation by the pparγ agonist rosiglitazone

    Stroke, Vol. 44, Núm. 12, pp. 3498-3508

  3. Neuronal excitotoxicity after carotid angioplasty and stent placement procedures

    Radiology, Vol. 268, Núm. 2, pp. 515-520

2012

  1. Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection

    Stroke, Vol. 43, Núm. 1, pp. 211-219

2011

  1. Longitudinal studies of ischemic penumbra by using 18F-FDG PET and MRI techniques in permanent and transient focal cerebral ischemia in rats

    NeuroImage, Vol. 57, Núm. 1, pp. 45-54

  2. Quantitative 1H MR spectroscopic imaging of the prostate gland using LCModel and a dedicated basis-set: Correlation with histologic findings

    Magnetic Resonance in Medicine, Vol. 65, Núm. 2, pp. 329-339

2009

  1. Synthesis of lipoxin A 4 by 5-lipoxygenase mediates pparγ-dependent, neuroprotective effects of rosiglitazone in experimental stroke

    Journal of Neuroscience, Vol. 29, Núm. 12, pp. 3875-3884

2008

  1. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke

    Circulation, Vol. 118, Núm. 14, pp. 1450-1459

2007

  1. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke

    Stroke, Vol. 38, Núm. 1, pp. 90-95

  2. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARγ target gene involved in neuroprotection

    Journal of Cerebral Blood Flow and Metabolism, Vol. 27, Núm. 7, pp. 1327-1338

  3. Statin treatment withdrawal in ischemic stroke: A controlled randomized study

    Neurology, Vol. 69, Núm. 9, pp. 904-910

2006

  1. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke

    Journal of Experimental Medicine, Vol. 203, Núm. 3, pp. 711-717